Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed (INSM) awaits a pivotal FDA decision on brensocatib for bronchiectasis. Strong ARIKAYCE growth contrasts with wider losses, shaping its future prospects.
Insmed's brensocatib nears potential FDA approval amid strong ARIKAYCE sales. Q4 losses spark caution, but analysts see potential. A deep dive into INSM's outlook.
Insmed awaits FDA decision on brensocatib (August 12, 2025). No advisory committee suggests streamlined approval. Q4 loss wider, but ARIKAYCE strong. Key insights inside.
Analysis of Insmed (INSM): FDA update on Brensocatib, ARIKAYCE sales, international strategies, and Q4 2024 financials. Actionable insights for investors.